Thrombolytic Science International LLC
Novel clot-dissolving drug for ischemic stroke
This article was originally published in Start Up
Thrombolytic Science International LLC’s drug candidate for acute post-stroke therapy is a mutant of pro-urokinase, a natural enzyme found in humans that, like tPA, also activates plasmin. TSI’s modified protein is designed to hold its inert, pro-enzymatic form longer in the bloodstream, enabling it to retain its occlusive clot specificity at higher, therapeutic doses with reduced risk of bleeding.